Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$6.6M Buy
26,234
+5,330
+25% +$1.15M 3.15% 1
2026
Q1
$4.55M Buy
20,904
+295
+1% +$65.4K 2.22% 8
2025
Q4
$4.71M Buy
20,609
+40
+0.2% +$9.11K 2.4% 5
2025
Q3
$4.76M Hold
20,569
2.57% 4
2025
Q2
$3.82M Buy
20,569
+589
+3% +$109K 2.22% 10
2025
Q1
$4.19M Buy
19,980
+380
+2% +$73.9K 2.49% 2
2024
Q4
$3.48M Buy
19,600
+230
+1% +$42.3K 2.26% 10
2024
Q3
$3.83M Buy
19,370
+205
+1% +$38.3K 2.52% 8
2024
Q2
$3.29M Sell
19,165
-137
-0.7% -$22.7K 2.35% 10
2024
Q1
$3.51M Sell
19,302
-1,005
-5% -$173K 2.47% 8
2023
Q4
$3.15M Sell
20,307
-230
-1% -$33.5K 2.4% 12
2023
Q3
$3.04M Buy
20,537
+470
+2% +$69K 2.66% 10
2023
Q2
$2.71M Sell
20,067
-1,335
-6% -$196K 2.38% 13
2023
Q1
$3.41M Buy
21,402
+284
+1% +$43.4K 3.11% 3
2022
Q4
$3.41M Sell
21,118
-164
-0.8% -$25.1K 3.11% 4
2022
Q3
$2.86M Buy
21,282
+220
+1% +$31.6K 2.84% 9
2022
Q2
$3.23M Sell
21,062
-1,005
-5% -$154K 2.95% 5
2022
Q1
$3.46M Sell
22,067
-2,050
-9% -$298K 2.82% 6
2021
Q4
$3.27M Buy
+24,117
New +$2.85M 2.91% 4

Other funds holding ABBV

Apricus Wealth's ABBV Position: Q2 2026 in Review

Apricus Wealth increased its AbbVie (ABBV) stake by 25% in Q2 2026, buying an estimated $1.15M and bringing the position to 26,234 shares worth $6.6M. The position accounts for 3.15% of the portfolio, ranked #1.

Apricus Wealth first reported a position in ABBV in Q4 2021 and has held it in 19 quarters since. 1,621 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Apricus Wealth held 26,234 shares of AbbVie worth $6.6M as of Q2 2026.
  • Apricus Wealth bought 5,330 AbbVie shares in Q2 2026, an estimated $1.15M.
  • AbbVie made up 3.15% of Apricus Wealth's portfolio in Q2 2026, its #1 holding.
  • Apricus Wealth first reported a position in AbbVie in Q4 2021 and has held it in 19 quarters since.
  • 1,621 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Apricus Wealth's 13F filing for Q2 2026, filed 22 Jul 2026.